Biological
SYN023 clinical trials
Also written SYN023.
- studies test it
- 4
- open now
- 0
- in phase 3
- 1
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Synermore Biologics Co., Ltd. (2) · Synermore Biologics (Suzhou) Co., Ltd. (2)
Often tested with
Tested in the same studies.
Rabies virus strain PM-1503-3M antigen (propiolactone inactivated) (1) · Rabies virus strain flury LEP antigen (propiolactone inactivated) (1)
Studies
Open first, then newest update. How each study uses SYN023 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of RabiesCompletedPhase 2Synermore Biologics Co., Ltd.NCT03961555Written as SYN023
- SYN023 With Rabies Vaccine in Healthy Pediatric SubjectsCompletedPhase 1Synermore Biologics (Suzhou) Co., Ltd.NCT07342257Written as SYN023
- A Phase III Clinical Study to Evaluate SYN023's Efficacy and SafetyCompletedPhase 3Synermore Biologics (Suzhou) Co., Ltd.NCT04644484Written as SYN023
- A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies VaccinesCompletedPhase 1/2Synermore Biologics Co., Ltd.NCT02956746Written as SYN023